Orchard raises $110M series B

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $110 million in a series B round led by Baillie Gifford and ORI Capital. Fellow new investors Temasek, Cowen Healthcare Investments, Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4BIO Capital also participated, as did existing investors F-Prime Capital and UCL Technology Fund.

Orchard said the round will fund the company into 2019, including the launch of lead program OTL-101, which is in Phase I/II testing to treat adenosine deaminase severe combined immunodeficiency (ADA-SCID), according to ClinicalTrials.gov. President and CEO Mark Rothera told BioCentury the company plans to submit a BLA in 2H18, and hopes to launch OTL-101 in the U.S. in 2019. The company also plans to submit regulatory applications in Europe in 1H19...